Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary

10/13/2020 | 02:01am EST

By Joshua Kirby

Nestle SA said Tuesday that it has bought a number of shares in Aimmune Therapeutics Inc., taking its holding in the pharmaceutical company to 84%.

The Swiss food-and-beverage conglomerate said its wholly-owned subsidiary SPN MergerSub had purchased around 43.4 million shares via a tender offer at a price of $34.50 per share. Added to the shares already owned by Nestle and its subsidiaries, it represents around 84% of the outstanding shares in Aimmune Therapeutics, the company said.

SPN MergerSub will be merged with Aimmune Therapeutics, which will continue as the surviving corporation, Nestle said.

Write to Joshua Kirby at joshua.kirby@dowjones.com

(END) Dow Jones Newswires

10-13-20 0200ET

Stocks mentioned in the article
ChangeLast1st jan.
AIMMUNE THERAPEUTICS, INC. -0.29% 34.49 End-of-day quote.3.05%
NESTLÉ S.A. -0.08% 102.3 Delayed Quote.-2.37%
All news about AIMMUNE THERAPEUTICS, INC.
10/21Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
10/19AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
10/19AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
10/15MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
10/15AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
10/13AIMMUNE THERAPEUTICS : Nestle announces results of tender offer for Aimmune Ther..
AQ
10/13GLOBAL MARKETS LIVE: U.S. banks beat expectations
10/13Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
DJ
10/13AIMMUNE THERAPEUTICS : shareholders accept $2 billion Nestle tender offer
RE
09/18Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -248 M - -
Net cash 2019 89,6 M - -
P/E ratio 2019 -8,43x
Yield 2019 -
Capitalization 2 268 M 2 268 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 339
Free-Float 77,8%
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 34,49 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Eric Hands Claude Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.3.05%2 268
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273